Like Britannia Industries, GSK Cons may hit Rs 6940: Ajay Bodke

Ajay Bodke of Prabhudas Lilladher told CNBC-TV18, "People are expecting a massive leg up in the consumption led demand due to pumping up roughly Rs 1.1 lakh crore on the basis of OROP as well as 7th Pay Commission recommendations as the Budgets singular focus on helping revive the rural sector by allocating Rs 87,000 crore. So, there two stocks in particular we like, one is Britannia Industries which has sort of been moving sideways over the last few months. So that is a stock which we have in the medium-term and expect a strong upside.""Last quarter for GlaxoSmithKline Consumer Healthcare was bit tepid because of the floods in Tamil Nadu which contributes a large chunk of its sales for Horlicks. However, this quarter we are expecting that to even out and the company to again go back into strong growth. So both these stocks would be our focus. Britannia with the medium-term target price of Rs 3,200 and GlaxoSmithKline with a medium-term price target of Rs 6,940," he said.